197 related articles for article (PubMed ID: 36074101)
1. The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose.
Lundine D; Annor GK; Chavez V; Maimos S; Syed Z; Jiang S; Ellison V; Bargonetti J
Mol Cancer Res; 2022 Dec; 20(12):1799-1810. PubMed ID: 36074101
[TBL] [Abstract][Full Text] [Related]
2. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Xiao G; Lundine D; Annor GK; Canar J; Ellison V; Polotskaia A; Donabedian PL; Reiner T; Khramtsova GF; Olopade OI; Mazo A; Bargonetti J
Cancer Res; 2020 Feb; 80(3):394-405. PubMed ID: 31776133
[TBL] [Abstract][Full Text] [Related]
3. Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity.
Ellison V; Annor GK; Freedman C; Xiao G; Lundine D; Freulich E; Prives C; Bargonetti J
Oncotarget; 2021 Jun; 12(12):1128-1146. PubMed ID: 34136083
[TBL] [Abstract][Full Text] [Related]
4. Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities.
Annor GK; Elshabassy N; Lundine D; Conde DG; Xiao G; Ellison V; Bargonetti J
Front Cell Dev Biol; 2021; 9():772315. PubMed ID: 34881245
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Gyan KK; Altorki NK; Cheng E; Ginter PS; Hoda S; Newman L; Elemento O; Olopade OI; Davis MB; Martin ML; Bargonetti J
Cancer Lett; 2024 Mar; 584():216608. PubMed ID: 38199587
[TBL] [Abstract][Full Text] [Related]
6. Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient.
Shtraizent N; Matsui H; Polotskaia A; Bargonetti J
Int J Environ Res Public Health; 2015 Dec; 13(1):ijerph13010022. PubMed ID: 26703669
[TBL] [Abstract][Full Text] [Related]
7. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.
Polotskaia A; Xiao G; Reynoso K; Martin C; Qiu WG; Hendrickson RC; Bargonetti J
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1220-9. PubMed ID: 25733866
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Olopade OI; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Gyan KK; Altorki NK; Cheng E; Ginter PS; Hoda S; Newman L; Elemento O; Davis MB; Martin ML; Bargonetti J
bioRxiv; 2023 Jun; ():. PubMed ID: 38076873
[TBL] [Abstract][Full Text] [Related]
9. Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer.
Qiu WG; Polotskaia A; Xiao G; Di L; Zhao Y; Hu W; Philip J; Hendrickson RC; Bargonetti J
NPJ Breast Cancer; 2017; 3():. PubMed ID: 28232952
[TBL] [Abstract][Full Text] [Related]
10. A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN.
Ellison V; Polotskaia A; Xiao G; Leybengrub P; Qiu W; Lee R; Hendrickson R; Hu W; Bargonetti J
bioRxiv; 2024 Jan; ():. PubMed ID: 38328189
[TBL] [Abstract][Full Text] [Related]
11. Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.
Xiao G; Annor GK; Fung K; Keinänen O; Zeglis BM; Bargonetti J
Mol Pharm; 2021 Jan; 18(1):338-346. PubMed ID: 33289569
[TBL] [Abstract][Full Text] [Related]
12. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
Cuddihy AR; Jalali F; Coackley C; Bristow RG
Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
14. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
Zhang L; Li DQ
Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribosyl)ation is required for p53-dependent signal transduction induced by radiation.
Wang X; Ohnishi K; Takahashi A; Ohnishi T
Oncogene; 1998 Dec; 17(22):2819-25. PubMed ID: 9879988
[TBL] [Abstract][Full Text] [Related]
16. The C-terminal domain of p53 orchestrates the interplay between non-covalent and covalent poly(ADP-ribosyl)ation of p53 by PARP1.
Fischbach A; Krüger A; Hampp S; Assmann G; Rank L; Hufnagel M; Stöckl MT; Fischer JMF; Veith S; Rossatti P; Ganz M; Ferrando-May E; Hartwig A; Hauser K; Wiesmüller L; Bürkle A; Mangerich A
Nucleic Acids Res; 2018 Jan; 46(2):804-822. PubMed ID: 29216372
[TBL] [Abstract][Full Text] [Related]
17. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells.
Yi YW; Kang HJ; Kim HJ; Kong Y; Brown ML; Bae I
Oncotarget; 2013 Jul; 4(7):984-94. PubMed ID: 23846322
[TBL] [Abstract][Full Text] [Related]
18. A quantitative assay reveals ligand specificity of the DNA scaffold repair protein XRCC1 and efficient disassembly of complexes of XRCC1 and the poly(ADP-ribose) polymerase 1 by poly(ADP-ribose) glycohydrolase.
Kim IK; Stegeman RA; Brosey CA; Ellenberger T
J Biol Chem; 2015 Feb; 290(6):3775-83. PubMed ID: 25477519
[TBL] [Abstract][Full Text] [Related]
19. Regulation of Poly(ADP-Ribose) Polymerase 1 Activity by Y-Box-Binding Protein 1.
Naumenko KN; Sukhanova MV; Hamon L; Kurgina TA; Alemasova EE; Kutuzov MM; Pastré D; Lavrik OI
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32947956
[TBL] [Abstract][Full Text] [Related]
20. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.
Puca R; Nardinocchi L; Porru M; Simon AJ; Rechavi G; Leonetti C; Givol D; D'Orazi G
Cell Cycle; 2011 May; 10(10):1679-89. PubMed ID: 21508668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
